Vimarsana
Biggest News Aggregation in the World

Page 17 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

FDA Approves Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria - Vimarsana News

FDA Approves Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria

The approval was based on data from the APPLY-PNH trial and APPOINT-PNH study, which showed iptacopan was superior for hemoglobin improvement in the absence of red blood cell transfusions and in transfusion avoidance rate compared to patients who stayed on anti-C5 treatments.

MOSIE BABY BECOMES THE FIRST COMPANY TO RECEIVE FDA CLEARANCE FOR AT-HOME INTRAVAGINAL INSEMINATION - Vimarsana News

MOSIE BABY BECOMES THE FIRST COMPANY TO RECEIVE FDA CLEARANCE FOR AT-HOME INTRAVAGINAL INSEMINATION

/PRNewswire/ -- Mosie Baby, a pioneering at-home fertility care company, has secured FDA Class II clearance for its Mosie Baby Kit making it the first and only...

Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer - Vimarsana News

Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD)...

Phathom Pharmaceuticals Announces Commercial Availability - Vimarsana News

Phathom Pharmaceuticals Announces Commercial Availability

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available at major retail pharmacies and through BlinkRx....

Gene editing will change medicine—and maybe health investing too - Vimarsana News

Gene editing will change medicine—and maybe health investing too

The first treatment based on the Nobel Prize-winning Crispr technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.